Synovics Pharmaceuticals EBIT

Synovics Pharmaceuticals (SYVC) currently reports a EBIT of $-1.9M as of July 2009. That compares with $-2M in the prior-year period — up 3.1% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Synovics Pharmaceuticals's EBIT history and peer comparisons.

Synovics Pharmaceuticals's EBIT increased from $-2M to $-1.9M — a 3.1% year-over-year increase (period ending July 2009). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Synovics Pharmaceuticals's EBIT of $-1.9M is lower than the Healthcare sector average of $130B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Synovics Pharmaceuticals reported $-1.9M in EBIT as of July 2009. That compares with $-2M in the prior-year period — up 3.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Synovics Pharmaceuticals, and consider following SYVC for alerts when major investors trade the stock.